The trailer is available here:

http://www.youtube.com/scottmillerandco

Squalene is a naturally occuring organic oil in cell walls.
Sharks are a good source for purified MF59 Squalene used in
vaccines.

Squalene in tissue fluid tells the immune system that a cell
has died. If concentrations of squalene are high enough, it starts
an immune response with white blood cells arriving to clean up the
mess.

With the Anthrax Vaccine – squalene binds to the
Anthrax Protective Antigen (APA). APA protects anthrax bacteria
and is the Trojan horse that breaks through cell walls so anthrax
can begin destroying healthy tissue.

Squalene lets a simple protein Furin remove the “safety cap” on APA.
This activates APA’s landing pads for the Anthrax Edema Factor and
two Anthrax Lethal Factor proteins, while unlocking APA’s
calcium-calcium reciprocal engine and unleashing the folded
protein chain that drills into healthy cell walls.

Squalene in the anthrax vaccine made it a dead certainty
that the immune response will find APA bound to FURIN –
which can lead to memory B-cells making FURIN-sequestering
Immunoglobulin Gamma antibodies.

If this happens, then (6) key growth factors will stop activating
in the human body: para-thyroid hormone, beta-secretase,
gonaditropin, transforming growth factor beta-1,
von Willebrand Factor, and nerve growth factor.

Depending on the body location of concentrations of subverted
Immunoglobulin Gamma,the following auto-immune diseases can appear
alone or in combination

Rheumatoid arthritis, vasculitis, Sjogren’s syndrome, ALS,
muscular sclerosis, scleroderma, tendonitis, tendon rupture,
severe amenorrhea, severe depression, chronic fatigue syndrome,
mitochrondial encephalopathy, lymphoma, skin cancer,
birth defects, and death.

The statistics indicate that one in three recipients of the human
anthrax vaccine will report some side effects. Two in every thousand
will have a severe life-threatening reaction to BioThrax.

For the military, this is often reported as severe depression
accompanied by chronic fatigue syndrome, leading to bad conduct
discharges and potentially death by suicide.

The human anthrax vaccine is NOT recommended by the FDA for women
of child-bearing age, children, and the elderly. Women have an
elevated chance of dying from severe amenorrhea during their next
period because of low levels of activated gonaditropin and
beta-secretase.

The human anthrax vaccine has NEVER been licensed for use to prevent
inhalation anthrax disease – since all tests to prove its efficacy in
animals have reported a failure rate of 75% in higher primate test
populations – as reported by Dr. Bruce Ivins in 1999 and 2000.

The presence of squalene in the BioThrax vaccine while confirmed in
(6) large batches in the late 1990s was stopped because it amplified the
the chance for the immune system to create Furin sequestering IgG.

Gary Matsumoto’s book “VACCINE A” exposes how Dr. Susan Welko and
Dr. Bruce Ivins of USAMRIID introduced squalene into the vaccine
to amplify the immune response to APA.

Variations of the squalene formulation were key to the OMER-2
tests that caused 1,500 Israeli Defense Force members to become
chronically ill beginning in 1998, which was jointly funded by
USAMRIID and Israel.

Antibodies that capture APA actually only slow down the onset of
anthrax disease – and DOES NOT help the human body identify and
attack anthrax bacteria.

BioThrax only provides a 1-year TEMPORARY TOLERANCE to low levels
of anthrax bacteria in the human body – and allows
soldiers to survive low-level exposure long enough so that they
can get back to a medical facility and be treated with inexpensive
doxycycline.

Alternatively, it lets vaccinated soldiers carry live anthrax into
enemy camps, which would circumvent the Biological Weapons Treaties.

BioThrax provides a 1-YEAR TEMPORARY TOLERANCE because if
FURIN sequestering antibodies are created, memory B-cell lines
will die off. Memory B-cells maintain the body’s supply of
antibodies. After 1-year, a soldier’s ability to withstand
any infection can be diminished by FURIN sequestering antibodies
caused by the human anthrax vaccine.

While this knowledge has been available to the US government
for many years, the official 2009 Department of Defense
continuing education course teaches health-care providers in
the military – that BioThrax is safe and effective against
anthrax disease – and is required to maintain a standing
fighting force. See: http://www.biothrax.com for the official
view of the human anthrax vaccine.

BioThrax is produced by Emergent Biosolutions of Rockville, MD,
through its division Emergent Biodefense located in Lansing, MI.

Emergent Biosolutions also controls distribution of the British
anthrax vaccine produced by the UK’s Health Protection Agency at
Porton Down, England.

Currently, Emergent Biosolutions is engaged in a lawsuit to gain
control of Protein Sciences Corporation – which is engaged in
the development of an H1N1 influenza vaccine – and is a potential winner
of a contract award worth $1 billion dollars from Health and Human
Services.

Emergent Biosolutions has taken over (7) bio-tech companies since
emerging from near bankruptcy in 2004, after being forced by the
FDA to implement inventory and quality controls at Emergent
Biosolutions that would finally meet FDA standards for distribution
licensing.

It is in the process of applying for Phase 1 testing of harvested
IgG from military personnel exposed to BioThrax – which it has
branded as the Anthrax Immunoglobulin Gamma (AIG) therapy.